Your browser doesn't support javascript.
loading
Meningioma: International Consortium on Meningiomas (ICOM) consensus review on scientific advances & treatment paradigms for clinicians, researchers, and patients.
Wang, Justin Z; Landry, Alexander P; Raleigh, David R; Sahm, Felix; Walsh, Kyle M; Goldbrunner, Roland; Yefet, Leeor S; Tonn, Jörg C; Gui, Chloe; Ostrom, Quinn T; Barnholtz-Sloan, Jill; Perry, Arie; Ellenbogen, Yosef; Hanemann, C Oliver; Jungwirth, Gerhard; Jenkinson, Michael D; Tabatabai, Ghazaleh; Mathiesen, Tiit I; McDermott, Michael W; Tatagiba, Marcos; la Fougère, Christian; Maas, Sybren L N; Galldiks, Norbert; Albert, Nathalie L; Brastianos, Priscilla K; Ehret, Felix; Minniti, Giuseppe; Lamszus, Katrin; Ricklefs, Franz L; Schittenhelm, Jens; Drummond, Katharine J; Dunn, Ian F; Pathmanaban, Omar N; Cohen-Gadol, Aaron; Sulman, Erik P; Tabouret, Emeline; Le Rhun, Emelie; Mawrin, Christian; Moliterno, Jennifer; Weller, Michael; Bi, Wenya Linda; Gao, Andrew; Yip, Stephen; Niyazi, Maximilian; Aldape, Kenneth; Wen, Patrick Y; Short, Susan; Preusser, Matthias; Nassiri, Farshad; Zadeh, Gelareh.
Afiliación
  • Wang JZ; MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada.
  • Landry AP; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada.
  • Raleigh DR; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Sahm F; MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada.
  • Walsh KM; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada.
  • Goldbrunner R; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Yefet LS; Department of Radiation Oncology, Neurological Surgery, and Pathology, University of California San Francisco, San Francisco, CA, USA.
  • Tonn JC; Department of Neuropathology, University Hospital Heidelberg and German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Gui C; Department of Neurosurgery, Duke University, Durham, NC, USA.
  • Ostrom QT; Center of Neurosurgery, Department of General Neurosurgery, University of Cologne, Cologne, Germany.
  • Barnholtz-Sloan J; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada.
  • Perry A; Department of Neurosurgery, University Hospital Munich LMU, Munich, Germany.
  • Ellenbogen Y; MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada.
  • Hanemann CO; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada.
  • Jungwirth G; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Jenkinson MD; Department of Neurosurgery, Duke University, Durham, NC, USA.
  • Tabatabai G; Central Brain Tumor Registry of the United States, Hinsdale, IL, USA.
  • Mathiesen TI; Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA.
  • McDermott MW; Central Brain Tumor Registry of the United States, Hinsdale, IL, USA.
  • Tatagiba M; Trans Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, Bethesda, MD, USA.
  • la Fougère C; Center for Biomedical Informatics & Information Technology (CBIIT), National Cancer Institute, Bethesda, MD, USA.
  • Maas SLN; Department of Pathology, University of California San Francisco, San Francisco, California, USA.
  • Galldiks N; MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada.
  • Albert NL; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada.
  • Brastianos PK; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Ehret F; Peninsula Schools of Medicine, University of Plymouth University, Plymouth, UK.
  • Minniti G; Division of Experimental Neurosurgery, Department of Neurosurgery, Heidelberg University, Heidelberg, Germany.
  • Lamszus K; Institute of Translational Medicine, University of Liverpool, UK.
  • Ricklefs FL; The Walton Centre NHS Foundation Trust, Liverpool, UK.
  • Schittenhelm J; Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Tübingen, Germany.
  • Drummond KJ; Cluster of Excellence (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", Eberhard Karls University Tübingen, Tübingen, Germany.
  • Dunn IF; Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University Tübingen, Tübingen, Germany.
  • Pathmanaban ON; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
  • Cohen-Gadol A; Miami Neuroscience Institute, Baptist Health of South Florida, Miami, FL, United States; Division of Neuroscience, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.
  • Sulman EP; Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Tübingen, Germany.
  • Tabouret E; Department of Neurosurgery, University of Tübingen, Tübingen, Germany.
  • Le Rhun E; Cluster of Excellence (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", Eberhard Karls University Tübingen, Tübingen, Germany.
  • Mawrin C; Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tübingen, Germany.
  • Moliterno J; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
  • Weller M; Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Bi WL; Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany and Institute of Neuroscience and Medicine (IMN-3), Research Center Juelich, Juelich, Germany.
  • Gao A; Department of Nuclear Medicine, Ludwig Maximilians-University of Munich, Munich, Germany.
  • Yip S; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Niyazi M; Berlin Institute of Health, Charité - Universitätsmedizin Berlin, Berlin, Germany; Department of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Aldape K; Laboratory for Brain Tumor Biology, University Hospital Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.
  • Wen PY; Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
  • Short S; Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Tübingen, Germany.
  • Preusser M; Department of Neuropathology, University Hospital Tübingen, Eberhard-Karls-University Tübingen, 72076 Tübingen, Germany.
  • Nassiri F; Department of Neurosurgery, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Zadeh G; Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Neuro Oncol ; 2024 May 02.
Article en En | MEDLINE | ID: mdl-38695575
ABSTRACT
Meningiomas are the most common primary intracranial tumors in adults and are increasing in incidence due to the aging population and the rising availability of neuroimaging. While most exhibit non-malignant behaviour, a subset of meningiomas are biologically aggressive and lead to significant neurological morbidity and mortality. In recent years, meaningful advances in our understanding of the biology of these tumors have led to the incorporation of molecular biomarkers into their grading and prognostication. However, unlike other central nervous system tumors, a unified molecular taxonomy for meningiomas has not yet been established and remains an overarching goal of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-Not Official WHO (cIMPACT-NOW) working group. There also remains clinical equipoise on how specific meningioma cases and patient populations should be optimally managed. To address these existing gaps, members of the International Consortium on Meningiomas (ICOM) including field-leading experts, have prepared a comprehensive consensus narrative review directed towards clinicians, researchers, and patients. Included in this manuscript are detailed overviews of proposed molecular classifications, novel biomarkers, contemporary treatment strategies, trials on systemic therapies, health-related quality of life studies, and management strategies for unique meningioma patient populations. In each section we discuss the current state of knowledge as well as ongoing clinical and research challenges to road map future directions for further investigation.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Neuro Oncol Asunto de la revista: NEOPLASIAS / NEUROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Neuro Oncol Asunto de la revista: NEOPLASIAS / NEUROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Canadá